Prosecution Insights
Prosecution Insights
5 pending office actions • 3 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (80%) |
| §112 only | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, SHENG HAN | 2 | 65.9% | +35.2% |
| BASQUILL, SEAN M | 1 | 38.6% | +22.5% |
| BRANDSEN, BENJAMIN MICHAEL | 1 | 61.5% | +17.0% |
| HIBSHMAN, SARAH GRACE | 1 | 40.9% | +46.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17913587 | COMPOSITION WHICH IS FOR TREATING OR PREVENTING RENAL CELL CANCER AND CONTAINS D-ALLOSE AS ACTIVE INGREDIENT, AND METHOD FOR TREATING OR PREVENTING CANCER USING SAME | HIBSHMAN, SARAH GRACE | 71d overdue |
| 18023988 | SURFACE-TREATED HYDROTALCITE, SUSPENSION OF SAME, AND FUNCTIONAL MOLECULE DELIVERY SYSTEM USING SAME | DAVIS, SHENG HAN | 42d overdue |
| 18284991 | CYTOKINE PRODUCTION SUPPRESSING COMPOSITION CONTAINING D-ALLOSE AS ACTIVE COMPONENT, AND METHOD OF TREATING OR PREVENTING DISEASE ASSOCIATED WITH CYTOKINE OVERPRODUCTION USING SAME | BRANDSEN, BENJAMIN MICHAEL | 31d overdue |
| 18279373 | ZINC-CONTAINING HYDROTALCITE | DAVIS, SHENG HAN | 18d overdue |
| 18685051 | MAGNESIUM OXIDE TABLETS | BASQUILL, SEAN M | 14d |
| Art Unit | Apps |
|---|---|
| 1693 | 2 |
| 1732 | 2 |
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18685051 | MAGNESIUM OXIDE TABLETS | BASQUILL, SEAN M | 1614 | §103 | Non-Final OA | 14d | Pending | Feb 20, 2024 |
| 18284991 | CYTOKINE PRODUCTION SUPPRESSING COMPOSITION CONTAINING D-ALLOSE AS ACTIVE COMPONENT, AND METHOD OF TREATING OR PREVENTING DISEASE ASSOCIATED WITH CYTOKINE OVERPRODUCTION USING SAME | BRANDSEN, BENJAMIN MICHAEL | 1693 | §112 | Non-Final OA | 31d overdue | Pending | Sep 29, 2023 |
| 18279373 | ZINC-CONTAINING HYDROTALCITE | DAVIS, SHENG HAN | 1732 | §103 | Non-Final OA | 18d overdue | Pending | Aug 29, 2023 |
| 18023988 | SURFACE-TREATED HYDROTALCITE, SUSPENSION OF SAME, AND FUNCTIONAL MOLECULE DELIVERY SYSTEM USING SAME | DAVIS, SHENG HAN | 1732 | §103 | Final Rejection | 42d overdue | Pending | Feb 28, 2023 |
| 17913587 | COMPOSITION WHICH IS FOR TREATING OR PREVENTING RENAL CELL CANCER AND CONTAINS D-ALLOSE AS ACTIVE INGREDIENT, AND METHOD FOR TREATING OR PREVENTING CANCER USING SAME | HIBSHMAN, SARAH GRACE | 1693 | §103 | Final Rejection | 71d overdue | Pending | Sep 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial